October 29, 2008
Westin Gaslamp Quarter Hotel
San Diego, CA
The Global Regulatory Summit brought together the knowledge and insight of thought leaders at regulatory agencies from around the world to give a global perspective on regulatory considerations in the development of oncology biologics products for the treatment of cancer. Representatives from regulatory agencies in the United States, Europe, Germany, Japan, India, Canada, China and others contributed to this program as members of the program committee and as faculty.
The Summit was designed to be a highly-interactive program complete with speakers from various regions of the world and a panel discussion involving not only the program speakers, but also invited experts from additional regulatory and related agencies. Speakers focused their presentations on their country's regulatory perspectives and requirements as well as addressing audience questions. A panel discussion concluded the program and addressed questions posed by both faculty members and the audience members in attendance.
Program Organizers |
|
|
Raj K. Puri, MD, PhD |
Ulrich Kalinke, PhD |
Intended Audience
Clinicians, industry representatives, government representatives, translational and basic scientists, graduate students, post-doctoral fellows, as well as other allied health professionals who are involved in clinical trials in the area of oncology biologics product development.
Program Goals
Expected Learner Outcomes
Upon completion of this activity, participants will be able to:
| 